ASTRA Raises €8.3M to Advance Animal Health Innovations

ASTRA Therapeutics, a Swiss BioTech startup focused on developing drugs against eukaryotic pathogens, has successfully raised a Seed funding round of €8.3 million. This round was led by MIG Capital AG with co-lead U.S. firm Digitalis Ventures. Other notable investors include Borealis Ventures, Kickfund, and Venture Kick. Positioned at the Park InnovAARE innovation campus, ASTRA has already developed a proprietary platform, ParaX, aimed at creating novel parasiticidal agents known as Parabulins. These agents specifically target crucial proteins in parasites, offering a substantial advantage due to increasing drug resistance in the current market. ASTRA is focused on targeting the veterinary market with its pipeline of over 15 patentable candidate classes for common parasites in farm animals and pets. With a lucrative global parasiticide market growing at 5.6% annually and a rise in drug-resistant cases, ASTRA aims to generate substantial revenue through strategic positioning and robust product development.